OXYBUTYNIN CHLORIDE (Page 2 of 4)

Pediatric

Pharmacokinetic information for pediatric patients 5 to 15 years of age with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) is approved for Alza Corporation’s oxybutynin chloride extended release tablets. However, due to Alza Corporation’s marketing exclusivity rights, this drug product is not labeled for pediatric use.

Gender

There are no significant differences in the pharmacokinetics of oxybutynin in healthy male and female volunteers following administration of oxybutynin chloride extended release tablets.

Race

Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on race in healthy volunteers following administration of oxybutynin chloride extended release tablets.

Renal Insufficiency

There is no experience with the use of oxybutynin chloride extended release tablets in patients with renal insufficiency.

Hepatic Insufficiency

There is no experience with the use of oxybutynin chloride extended release tablets in patients with hepatic insufficiency.

Drug-Drug Interactions

See PRECAUTIONS: Drug Interactions.

CLINICAL STUDIES

Oxybutynin chloride extended release tablets were evaluated for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in three controlled studies and one open-label study. The majority of patients were Caucasian (89.0%) and female (91.9%) with a mean age of 59 years (range, 18 to 98 years). Entry criteria required that patients have urge or mixed incontinence (with a predominance of urge) as evidenced by ≥ 6 urge incontinence episodes per week and ≥ 10 micturitions per day. Study 1 was a fixed-dose escalation design, whereas the other studies used a dose-adjustment design in which each patient’s final dose was adjusted to a balance between improvement of incontinence symptoms and tolerability of side effects. Controlled studies included patients known to be responsive to oxybutynin or other anticholinergic medications, and these patients were maintained on a final dose for up to 2 weeks.

The efficacy results for the three controlled trials are presented in the following tables and figures.

Number of Urge Urinary Incontinence Episodes Per Week
Study 1NOxybutynin Cl ER TabletsNPlacebo
*
Covariate adjusted mean with missing observations set to baseline values
The difference between Oxybutynin Chloride ER Tablets and placebo was statistically significant.
Mean Baseline3415.91620.9
Mean (SD) Change from Baseline *34-15.8 (8.9)16-7.6 (8.6)
95% Confidence Interval for Difference(-13.6,-2.8)
(Oxybutynin Chloride ER Tablet- Placebo)
Figure 2
(click image for full-size original)
Study 2NOxybutynin Cl ER TabletsNOxybutynin
*
Covariate adjusted mean with missing observations set to baseline values
Mean Baseline5327.65223.0
Mean (SD) Change from Baseline *53-17.6 (11.9)52-19.4 (11.9)
95% Confidence Interval for Difference(-2.8, 6.5)
(Oxybutynin Chloride ER Tablet- Oxybutynin)
Figure 3
(click image for full-size original)
Study 3NOxybutynin Cl ER TabletsNOxybutynin
*
Covariate adjusted mean with missing observations set to baseline values
The difference between oxybutynin chloride ER tablets and oxybutynin fulfilled the criteria for comparable efficacy.
Mean Baseline11118.911519.5
Mean (SD) Change from Baseline *111-14.5 (8.7)115-13.8 (8.6)
95% Confidence Interval for Difference(-3.0, 1.6)
(Oxybutynin Chloride ER Tablet- Oxybutynin)
Figure 4
(click image for full-size original)

OXYBUTYNIN CHLORIDE Indications and Usage

Oxybutynin chloride extended release tablets are once-daily controlled-release tablets indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Pediatric use information for the treatment of patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) is approved for Alza Corporation’s oxybutynin chloride extended release tablets. However, due to Alza Corporation’s marketing exclusivity rights, this drug product is not labeled for pediatric use.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.